EEG topography and tomography (LORETA) in the classification and evaluation of the pharmacodynamics of psychotropic drugs

Clinical EEG and Neuroscience

Volumn 37, Issue 2, 2006, Pages 66-80

  Saletu, Bernd ^a,b   Anderer, Peter ^a   Saletu Zyhlarz, Gerda M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Classification, Psychotropic Substances; Dose Efficacy Relations; EEG Mapping; EEG Tomography; Low Resolution Brain Electromagnetic Tomography (LORETA); Neuropsychopharmacology; Time Efficacy Relations

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZAMIDE DERIVATIVE; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; IMIPRAMINE; LORAZEPAM; METHYLPHENIDATE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PLACEBO; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; REMOXIPRIDE; S ADENOSYLMETHIONINE; SURICLONE; TIANEPTINE; TRANQUILIZER; UNINDEXED DRUG; VENLAFAXINE;

BIOAVAILABILITY; BRAIN ELECTROPHYSIOLOGY; BRAIN MAPPING; CLINICAL TRIAL; COMPUTER ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; ELECTROENCEPHALOGRAPHY; HUMAN; KEY LOCK PRINCIPLE; LOW DRUG DOSE; LOW RESOLUTION BRAIN ELECTROMAGNETIC TOMOGRAPHY; MENTAL DISEASE; MENTAL PATIENT; METHODOLOGY; NEUROIMAGING; NEUROLOGY; NEUROPHARMACOLOGY; NONHUMAN; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOELECTROENCEPHALOGRAPHY; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOLOGY; QUANTITATIVE ANALYSIS; REVIEW; SEDATION; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; THEORY; THERAPEUTIC MONITORING; TOMOGRAPHY; TOPOGRAPHY;

EID: 33646548234     PISSN: 00099155     EISSN: None     Source Type: Journal    
DOI: 10.1177/155005940603700205     Document Type: Review

References (105)

1. Berger H. Über das Elektroencephalogramm des Menschen. Arch Psychiatr Nervenkr 1934; 102: 538-557.
2. Bente D, Itil TM. Zur Wirkung des Phenothiazinkörpers Megaphen auf das menschliche Hirnstrombild. Arzneimittelforschung 1954; 4: 418-423.
3. Fink M. EEG and behavioral effects of psychopharmacology agents. In: Bradley PB, Deniker P, Radouco-Thomas C, (eds). Neuropsychopharmacology. Amsterdam: Elsevier; 1959; 1: 441-446.
4. Itil TM. Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In: Itil TM, (ed). Psychotropic Drugs and the Human EEG: Modern Problems of Pharmacopsychiatry. Basel: Karger; 1974: 43-75.
5. Fink M. Cerebral electrometry-quantitative EEG applied to human psychopharmacology. In: Dolce G, Künkel H, (eds). Computerized EEG analysis. Stuttgart: Fischer Verlag; 1975: 271-288.
6. Saletu B. Psychopharmaka, Gehirntätigkeit und Schlaf. Basel: Karger; 1976.
7. Herrmann WM. Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs. In: Herrmann WM, (ed). Electroencephalography in Drug Research. Stuttgart-New York: Gustav Fischer; 1982: 249-351.
8. Saletu B. The use of pharmaco-EEG in drug profiling. In: Hindmarch I, Stonier PD, (eds). Human Psychopharmacology, Measures and Methods. Chichester-New York-Brisbane-Toronto-Singapore: John Wiley&Sons; 1987; 1: 173-200.
9. Duffy FH, Bartels PH, Burchfiel JL. Significance probability mapping: An aid in the topographic analysis of brain electrical activity. Electroencephalogr Clin Neurophysiol 1981; 51: 455-462.
10. Buchsbaum MS, Hazlett E, Sicotte, Stein M, Wu J, Zetin M. Topographic EEG changes with benzodiazepine administration in generalized anxiety disorder. Biol Psychiatry 1985; 20: 832-842.
11. Itil TM, Shapiro DM, Eralp E, Akmann A, Itil KZ, Garbizu C. A new brain function diagnostic unit, including the dynamic brain mapping of computer-analyzed EEG, evoked potentials and sleep (a new hardware/software system and its application in psychiatry and psychopharmacology). New Trends Exp Clin Psychiatry 1985; 1: 107-177.
12. Anderer P, Saletu B, Kinsperger K, Semlitsch H. Topographic brain mapping of EEG in neuropsychopharmacology. I. Methodological aspects. Meth Find Exp Clin Pharmacol 1987; 9(6): 371-384.
13. Saletu B, Anderer P, Kinsperger K, Grünberger J. Topographic brain mapping of EEG in neuropsychopharmacology. II. Clinical applications (pharmaco EEG imaging). Meth Find Exp Clin Pharmacol 1987; 9(6): 385-408.
14. John ER, Prichep LS, Fridman J, Easton P. Neurometrics: computer-assisted differential diagnosis of brain dysfunctions. Science 1988; 239: 162-169.
15. Saletu B, Anderer P, Grünberger J. Topographic brain mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 1990; 11: 1-22.
16. Saletu B, Küfferle B, Anderer P, Grünberger J, Steinberger K. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms: comparative studies with remoxipride/haloperidol. Europ Neuropsychopharmacol 1990; 1: 27-36.
17. Maurer K, Dierks T. Atlas of Brain Mapping: Topographic Mapping of EEG and Evoked Potentials. Berlin - Heidelberg - New York - London - Paris - Tokyo - Hong Kong - Barcelona - Budapest: Springer-Verlag; 1991.
18. Saletu B, Darragh A, Breuel HP, Herrmann WM, Salmon P, Coen R, Anderer P. EEG mapping central effects of multiple doses of linopirine - a cognitive enhancer-in healthy elderly male subjects. Human Psychopharmacol Clin Exp 1991; 6: 267-275.
19. Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, et al. EEG brain mapping in diagnostic and therapeutic assessment of dementia. Alzheimer Dis Assoc Disord 1991; 5(suppl 1): 57-75.
20. Saletu B, Grünberger J, Linzmayer L, Anderer P, Semlitsch HV. EEG brain mapping and psychometry in age-associated memory impairment after acute and 2-week infusions with the hemoderivative Actovegin®: double-blind, placebo-controlled trials. Neuropsychobiology 1991; 24: 135-148.
21. Dierks T, Engelhardt W, Maurer K. Equivalent dipoles of FFT data visualize drug interaction at benzodiazepine receptors. Electroencephalogr Clin Neurophysiol 1993; 86(4): 231-237.
22. Lehmann D, Wackermann J, Michel CM, Koenig T. Space-oriented EEG segmentation reveals changes in brain electric field maps under the influence of a nootropic drug. Psychiatry Res 1993; 50(4): 275-282.
23. Galderisi S, Mucci A, Bucci P, Mignone ML, Maj M. Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Res 1996; 67(2): 113-122.
24. Saletu B, Brandstätter N, Metka M, Stamenkovic M, Anderer P, Semlitsch HV, et al. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas 1996; 23(1): 91-105.
25. Saletu B, Grünberger J, Anderer P, Linzmayer L, Zyhlarz G. Comparative pharmacodynamic studies with the novel serotonin uptake-enhancing tianeptine and -inhibiting fluvoxamine utilizing EEG mapping and psychometry. J Neural Transm 1996; 103: 191-216.
26. Saletu B. Visualizing the living human brain: the techniques and promise of EEG and event-related potentials mapping. In: Judd L, Saletu B, Filip V, (eds). Basic and Clinical Science of Mental and Addictive Disorders. Bibliotheca Psychiatrica No. 167. Basel: Karger; 1997: 54-62.
27. Saletu-Zyhlarz GM, Saletu B, Anderer P, Brandstätter N, Frey R, Gruber G, et al. Nonorganic insomnia in generalized anxiety disorder. I. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology 1997; 36: 117-129.
28. Prichep LS, Alper KR, Sverdlov L, Kowalik SC, John ER, Merkin H, et al. Outcome related electrophysiological subtypes of cocaine dependence. Clin Electroencephalogr 2002; 33(1): 8-20.
29. John ER, Prichep LS. The anesthetic cascade: a theory of how anesthesia suppresses consciousness. Anesthesiology 2005; 102: 447-471.
30. Pascual-Marqui RD, Michel CM, Lehmann D. Low resolution electromagnetic tomography: a new method for localizing electrical activity in the brain. Int J Psychophysiol 1994; 18: 49-65.
31. Pascual-Marqui RD, Lehmann D, Koenig T, Kochi K, Merlo MCG, Hell D, Koukkou M. Low resolution brain electromagnetic tomography (LORETA) functional imaging in acute, neuroleptic-naïve, first-episode, productive schizophrenia. Psychiatry Res Neuroimaging 1999; 90: 169-179.
32. Maurer K. Topographic brain mapping of EEG and evoked potentials. Berlin-Heidelberg-New York-London-Paris-Tokyo: Springer Verlag; 1989.
33. Anderer P, Semlitsch HV, Saletu B, Barbanoj MJ. Artifact processing in topographic mapping of electroencephalographic activity in neuropsychopharmacology. Psychiatry Res 1992; 45: 79-93.
34. Stille H, Herrmann WM. Guidelines for pharmaco-EEG studies in man. Pharmacopsychiatria 1982; 15: 107-108.
35. Herrmann WM, Abt K, Coppola R, Etevenon ET, Gerber G, Fink M, et al. International Pharmaco-EEG Group (IPEG): recommendations for EEG and evoked potential mapping. Neuropsychobiology 1989; 22: 170-176.
36. Saletu B, Krijzer F, Ferber G, Anderer P, (eds). Electrophysiological Brain Research in Preclinical and Clinical Pharmacology and Related Fields: An Update. Wien: Facultas Universitätsverlag; 2000.
37. Ferber G, Abt K, Fichte K, Luthringer R. IPEG guideline on statistical design and analysis for pharmacodynamic trials. International Pharmaco-EEG Group. Neuropsychobiology 1999; 39(2): 92-100.
38. Anderer P, Saletu B, Pascual-Marqui RD. Effect of the 5-HT1A partial agonist buspirone on regional brain electrical activity in man: a functional neuroimaging study using low-resolution electromagnetic tomography (LORETA). Psychiatry Res Neuroimag 2000; 100: 81-96.
39. Saletu B, Anderer P, Di Padova C, Assandri A, Saletu-Zyhlarz GM. Electrophysiological neuroimaging of the central effects of S-adenosyl-L- methionine by mapping of electroencephalograms and event-related potentials and low-resolution brain electromagnetic tomography. Am J Clin Nutr 2002; 76(suppl): 1162S-1171S.
40. Saletu B, Anderer P, Saletu-Zyhlarz GM, Gruber D, Metka M, Huber J. Identifying target regions for vigilance improvement under hormone replacement therapy in postmenopausal syndrome patients by EEG-LORETA (low-resolution brain electromagnetic tomography). Psychopharmacology 2005; 178(4): 389-399.
41. Saletu B, Anderer P, Saletu-Zyhlarz GM, Pascual-Marqui RD. EEG mapping and low-resolution brain electromagnetic tomography (LORETA) in diagnosis and therapy of psychiatric disorders: evidence for a key-lock principle. Clin EEG Neurosci 2005; 36(2): 108-115.
42. Saletu M, Anderer P, Saletu-Zyhlarz GM, Mandl M, Arnold O, Zeitlhofer J, Saletu B. EEG-tomographic studies with LORETA on vigilance differences between narcolepsy patients and controls and subsequent double-blind, placebo-controlled studies with modafinil. J Neurol 2004; 251: 1354-1363.
43. Saletu B, Barbanoj MJ, Anderer P, Sieghart W, Grünberger J. Clinical-pharmacological study with the two isomers (d-, I-) of fenfluramine and its comparison with chlorpromazine and d-amphetamine: blood levels, EEG mapping and safety evaluation. Meth Find Exp Clin Pharmacol 1993; 15(5): 291-312.
44. Saletu B, Küfferle B, Grünberger J, Földes P, Topitz A, Anderer P. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine. Neuropsychobiology 1994; 29: 125-135.
45. Koukou M. EEG correlates of information processing in acute schizophrenics. Adv Biol Psychiatry 1980; 4: 102-110.
46. Scharfetter C. Dissoziation und Schizophrenie: Fortschritte in Neurologie und Psychiatrie 1998; 66: 520-523.
47. Weinberger D.R. A connectionist approach to the prefrontal cortex. J Neuropsychiatry Clin Neurosci 1993; 5: 241-253.
48. Friston KJ. Theoretical neurobiology and schizophrenia. Br Med Bull 1996; 52: 644-655.
49. Katz M, Buchsbaum MS, Siegel BV, Wu J, Haier RJ, Bunney WE Jr. Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics. Neuropsychobiology 1996; 33: 1-11.
50. Liddle PF. Functional imaging-schizophrenia. Br Med Bull 1996; 52: 486-494.
51. Andreasen NC, O'Leary DS, Flaum M, Nopoulos P, Watkins GL, Boles Ponto LL, Hichwa RD. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997; 349: 1730-1734.
52. Koukkou M, Lehmann D, Wackermann J, Dvorak I, Henggeler B. Dimensional complexity of EEG brain mechanisms in untreated schizophrenia. Biol Psychiatry 1993; 33: 397-407.
53. Swanson CL, Harper Mozley LM, Gur RE. Positron emission tomography studies of cerebral metabolism and blood flow in schizophrenia. In: Krishnan KRR, Doraiswamy PM, (eds). Brain Imaging in Clinical Psychiatry. New York: Marcel Dekker; 1997: 401-424.
54. Cassady SL, Adami H, Moran M, Kunkel R, Thaker GK. Spontaneous dyskinesia in subjects with schizophrenic spectrum personality. Am J Psychiatry 1998; 155: 70-75.
55. Stuve TA, Friedmann L, Jesberger JA, Gilmore GC, Strauss MA, Meltzer HY. The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls. Psychol Med 1997; 27: 143-152.
56. Johannsen P, Jakobsen J, Bruhn P, Hansen SB, Gee A. Stokildejorgensen H. Gjedde A. Cortical sites of sustained and divided attention in normal elderly humans. Neuroimage 1997; 6: 145-155.
57. Saletu B, Grünberger J, Linzmayer L, Dubini A. Determination of pharmacodynamics of the new neuroleptic zetidoline by neuroendocrinologic, pharmaco-EEG, and psychometric studies. Part I. Int J Clin Pharmcol Ther Toxicol 1983; 21: 489-495.
58. Saletu B, Grünberger J, Anderer P, Linzmayer L, Semlitsch HV, Magni G. Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology. Br J Clin Pharmac 1992; 33: 589-601.
59. Saletu-Zyhlarz GM, Anderer P, Unzmayer L, Semlitsch HV, Assandri A, Prause W, et al. Visualizing central effects of S-adenosyl-L-methionine (SAMe), a natural molecule with anti-depressant properties, by pharmaco-EEG mapping. Int J Neuropsychopharmacol 2002; 5(3): 199-215.
60. th ed. München: Landsberg; 1986:1-71.
61. Arato M, Frecska E, MacCrimmon DJ, Guscott R, Saxena B, Tekes K, Tothfalusi L. Serotonergic interhemispheric asymmetry: neurochemical and pharmaco-EEG evidence. Prog Neuro-Psychopharmacol Biol Psychiat 1991; 15: 759-764.
62. Flor-Henry P. Observations, reflections and speculation on the cerebral determinants of mood and on the bilaterally asymmetrical distribution of the major neurotransmitter systems. In: Dewhurst WG, Baker GB, (eds). Pharmacotherapy of Affective Disorders: Theory and Practice. London, Sydney: Croom Heim; 1985: 151-184.
63. MacCrimmon DJ, Arato M. Interhemispheric serotonergic asymmetry in topographic pharmaco-EEG. Psychiat Res Neuroimag 1991; 40: 91-93.
64. Lader M, Melhuish A, Frcka G, Fredricson-Overo K, Christensen V. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 1986; 31(2): 183-190.
65. Van der Linden G, Van Heerden B, Warwick J, Wessels C, Van Kradenburg J, Zungu-Dirwayi N, Stein DJ. Functional brain imaging and pharmacotherapy in social phobia: single photon emission computed tomography before and after treatment with the selective serotonin reuptake inhibitor citalopram. Prog Neuro-Psychopharmacol Biol Psychiat 2000; 24: 419-438.
66. Saletu B, Anderer P, Kinsperger K, Grünberger J, Sieghart W. Comparative bioavailability studies with a new mixed-micelles solution of diazepam utilizing radioreceptor assay, psychometry and EEG brain mapping. Int Clin Psychopharmacol 1988; 3: 287-323.
67. Saletu B, Grünberger J, Anderer P, Barbanoj MJ. Pharmacodynamic studies of a combination of lorazepam and diphenhydramine and its single components: electroencephalographic brain mapping and safety evaluation. Curr Therapeutic Res 1988; 44(6): 909-937.
68. Saletu B, Grünberger J, Linzmayer L, Anderer P. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain - a kava plant derivative. Hum Psychopharmacol 1989; 4: 169-190.
69. Saletu B, Grünberger J, Linzmayer L, Semlitsch HV, Anderer P, Chwatal K. Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry. Br J Clin Pharmacol 1994; 37: 145-156.
70. Barbanoj MJ, Anderer P, Antonijoan RM, Torrent J, Saletu B, Jane F. Topographic pharmaco-EEG mapping of increasing doses of buspirone and its comparison with diazepam. Hum Psychopharmacol 1994; 9: 101-109.
71. Saletu B, Grünberger J, Berner P, Koeppen D. On differences between 1,5- and 1,4-benzodiazepines: pharmaco- EEG and psychometric studies with clobazam and lorazepam. In: Hindmarch I, Stonier PD, Trimble MR, (eds). Clobazam: Human Psychopharmacology and Clinical Applications, International Congress and Symposium Series, Nr 74. London: Royal Society of Medicine; 1985: 23-46.
72. Nobuhara K, Yagyu T, Kinoshita T. Diazepam effects on brain electric fields using LORETA (low resolution electromagnetic tomography). Psychiatry Res Neuroimag 1998; 83: 49-50.
73. Pauli S, Sedvall G. Three-dimensional visualization and quantification of the benzodiazepine receptor population within a living human brain using PET and MRI. Eur Arch Psychiatry Clin Neurosci 1997; 247: 61-70.
74. De Wit H, Metz J, Wagner N, et al. Effects of diazepam on cerebral metabolism in normal volunteers. Neuropsychopharmacology 1991; 5: 33-41.
75. Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson JC. PET in generalized anxiety disorder. Biol Psychiatry 1991; 29(12): 1181-1199.
76. Nordahl TE, Semple WE, Gross M, et al. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 1990; 3: 261-273.
77. Reiman EM, Raichle ME, Butler FK, et al. A focal brain disorder in panic disorder, a severe form of anxiety. Nature 1984; 310: 683-685.
78. Saletu B, Anderer P, Saletu-Zyhlarz GM, Pascual-Marqui RD. EEG topography and tomography in diagnosis and treatment of mental disorders: evidence for a key-lock principle. Methods Find Exp Clin Pharmacol 2002b; 24(suppl D): 97-106.
79. Tiihonen J, Kuikka J, Rasanen P, et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 1997; 2(6): 463-471.
80. 99mTc-HMPAO SPECT in patients with depressive disorders at rest: differential correlates with ratings of anxiety. Psychiatry Res Neuroimag 2000; 98: 43-54.
81. Buchsbaum MS, Wu J, Haier R, et al. Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder. Life Sci 1987; 40: 2393-2400.
82. Mathew RJ, Wilson WH. Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. Psychiatry Res Neuroimag 1991; 40: 125-134.
83. Grünberger J, Saletu B, Linzmayer L, Stöhr H. Objective measures in determining the central effectiveness of a new antihypoxidotic SL-76188: pharmaco-EEG, psychometric and pharmacokinetic analyses in the elderly. Arch Gerontol Geriatr 1982; 1: 261-285.
84. Saletu B, Grünberger J, Linzmayer L. Is amezinium methylsulfate - a new antihypotensive drug-psychoactive? Comparative quantitative EEG and psychometric trials with desipramine and methamphetamine. Curr Therapeutic Res 1980; 28: 800-826.
85. Saletu B, Grünberger J, Linzmayer L, Stöhr H. Pharmaco-EEG, psychometric and plasma level studies with two novel alpha-adrenergic stimulants CRL 40476 and 40028 (Adrafinil) in elderlies. New Trends Exp Clin Psychiat 1986; 2: 5-31.
86. Etevenon P, Peron-Magnan JP, Boulenger JP, Tortrat D, Guillou S, Toussaint M, et al. EEG cartography profile of caffeine in normals. Clin Neuropharmacol 1986; 9: 538-540.
87. Volkow ND, Wang GJ, Fowler JS, Galley SJ, Logan J, Ding YS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155(10): 1325-1331.
88. Head H. The conception of nervous and mental energy. II. Vigilance: a physiological state of the nervous system. Br J Psychol 1923; 14: 125-147.
89. Saletu B, Darragh A, Salmon P, Coen R. EEG brain mapping in evaluating the time-course of the central action of DUP 996 - a new acetylcholine-releasing drug. Br J Clin Pharmacol 1989; 28: 1-16.
90. Fischhof PK, Saletu B, Rüther E, Litschauer G, Môslinger- Gehmayr R, Herrmann WM. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). Neuropsychobiology 1992; 26: 65-70.
91. Saletu B, Anderer P, Semlitsch HV, Grünberger J, Linzmayer L, Chaudhry HR. Amantadine infusions in mild dementia: acute double-blind placebo-controlled EEG mapping and psychometric studies. Arch Gerontol Geriatr 1992; 15: 43-58.
92. Saletu B, Grünberger J, Linzmayer L, Anderer P. Dose-response studies with co-dergocrine mesylate under hypoxia utilizing EEG mapping and psychometry. Psychopharmacology 1992; 109: 30-40.
93. Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Böhmer F. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. Biol Psychiatry 1992; 32: 668-681.
94. Saletu B. EEG/EP mapping in neurodegenerative and cognitive disorders. In: Racagni G, Brunello N, Langer SZ, (eds). Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. Basel-Freiburg-Paris- London-New York-New Delhi-Bangkok-Singapore-Tokyo-Sydney: Karger; 1994: 24-30.
95. Saletu B, Saletu M, Brown M, Stern J, Sletten I, Ulett GA. Hypno-analgesia and acupuncture analgesia: a neurophysiological reality? Neuropsychobiology 1975; 1: 218-242.
96. Saletu B, Anderer P, Linzmayer L, Semlitsch HV, Lindeck-Pozza E, Assandri A, et al. Pharmacodynamic studies on the central mode of action of S-adenosyl-L-methionine (SAMe) infusions in elderly subjects, utilizing EEG mapping and psychometry. J Neural Transm 2002; 109:1505-1526.
97. Saletu B, Küfferle B, Grünberger J, Anderer P. Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy. Pharmacopsychiatry 1986; 19: 434-437.
98. Saletu B, Saletu M, Grünberger J, Mader R. Drawing inferences about the therapeutic efficacy of drugs in patients from their CNS effect in normals: comparative quantitative pharmaco-EEG and clinical investigations. In: Saletu B, Berner P, Hollister L, (eds). Neuro-Psychopharmacology. Oxford: Pergamon Press; 1979; 393-407.
99. Saletu B, Grünberger J, Volavka J, Berner P. Classification and bioavailability studies with WE 941 by quantitative pharmaco-EEG and clinical analyses. Arzneim Forsch Drug Res 1979; 29: 700-704.
100. Saletu B, Grünberger J, Saletu M, Mader R, Karobath M. The acute drug effect as predictor of therapeutic outcome: neurophysiological/behavioral correlations during anxiolytic therapy of alcoholics. In: Adv Biol Psychiatry. Basel: Karger; 1982; 9: 67-80.
101. Saletu B, Grünberger J. On acute and chronic CNS effects of antidepressants in normals: neurophysiological, behavioral and pharmacokinetic studies with pirlindol. Meth Find Exp Clin Pharmacol 1985; 7: 137-151.
102. Saletu B, Grunberger J, Rajna P, Stöhr H. Vigilanzverbesserung bei alternden Menschen: Doppelblinde, placebokontrollierte neurophysiologische und psychometrische Studien mit Pridoxilat. Therapiewoche 1982; 32: 5590-5603.
103. Saletu B, Saletu M, Grunberger J, Mader R. Spontaneous and drug-induced remission of alcoholic organic brain syndrome. Psychiatry Res 1983; 10: 59-75.
104. Saletu B, Saletu-Zyhlarz GM, Anderer P, Brandstätter N, Frey R, Gruber G, et al. Nonorganic insomnia in generalized anxiety disorder. II. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium®) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods. Neuropsychobiology 1997; 36: 130-152.
105. Saletu B, Paulus E, Linzmayer L, Anderer P, Semlitsch HV, Grunberger J, et al. Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: a double-blind, placebo-controlled, clinical and EEG/ERP mapping study. Psychopharmacology 1995; 117: 385-395.